Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 461


Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.

Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, Kim BS, Yoo MW, Yook JH, Kim BS, Kim KH, Kim CW, Kang YK.

Cancer Med. 2019 Jan 28. doi: 10.1002/cam4.1994. [Epub ahead of print]


[Gastrointestinal Stromal Tumor of the Small Intestine with Dissemination Successfully Treated with Surgical Resection and Adjuvant Chemotherapy with Sunitinib-A Case Report].

Obara S, Nakayama H, Kato T, Yamada T, Nakamura Y, Nishimura T, Kito Y, Okamura R.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2438-2440. Japanese.


Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.

Lu T, Chen C, Wang A, Jiang Z, Qi Z, Hu Z, Hu C, Liu F, Wang W, Wu H, Wang B, Wang L, Qi S, Wu J, Wang W, Tang J, Yan H, Bai M, Liu Q, Liu J.

Cancer Lett. 2019 Apr 10;447:105-114. doi: 10.1016/j.canlet.2019.01.024. Epub 2019 Jan 24.


Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor: A case report.

Nie Y, Sun W, Xiao Z, Ye S.

Medicine (Baltimore). 2019 Jan;98(3):e14060. doi: 10.1097/MD.0000000000014060.


Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand.

Bussabawalai T, Thiboonboon K, Teerawattananon Y.

Cost Eff Resour Alloc. 2019 Jan 8;17:1. doi: 10.1186/s12962-018-0169-9. eCollection 2019.


PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.

Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Exp Med. 2018 Dec 6. doi: 10.1007/s10238-018-0541-2. [Epub ahead of print]


[Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].

Wang L, Xu W, Yao X, Yan C, Li C, Zhu Z, Liu W, Yan M.

Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Nov 25;21(11):1274-1279. Chinese.


Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy.

Omari J, Drewes R, Matthias M, Mohnike K, Seidensticker M, Seidensticker R, Streitparth T, Ricke J, Powerski M, Pech M.

Brachytherapy. 2019 Jan - Feb;18(1):63-70. doi: 10.1016/j.brachy.2018.09.006. Epub 2018 Oct 29.


Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.

Yang W, Li K, Yu J, Shou C, Zhang Q, Hong Y, Sun J, Yu H, Gao Y, Shen Q, Zhao Z, Zheng S.

Scand J Gastroenterol. 2018 Oct - Nov;53(10-11):1328-1334. doi: 10.1080/00365521.2018.1518484. Epub 2018 Oct 22.


Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.

Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1.


Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review.

Tan S, Chen P, Ji J, Guo S, Yu D, Asakawa T, Zhou Y, Abe M, Zong L.

Dis Markers. 2018 Aug 26;2018:1368617. doi: 10.1155/2018/1368617. eCollection 2018.


Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.

Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA.

Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018.


The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.

Franck C, Rosania R, Franke S, Haybaeck J, Canbay A, Venerito M.

Digestion. 2019;99(2):179-184. doi: 10.1159/000490886. Epub 2018 Sep 4.


Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.

Zhang X, Zhou Y, Wu X, Nie M, Zhang B, Zhou Y, Sun L, Liu Z, Liu X, Kou Y, Wang Y, Zhang Y, Hao C, Shen L, Li J.

Eur J Surg Oncol. 2019 Mar;45(3):318-323. doi: 10.1016/j.ejso.2018.08.001. Epub 2018 Aug 11. Review.


BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.

Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT.

Cancer Sci. 2018 Nov;109(11):3591-3601. doi: 10.1111/cas.13773. Epub 2018 Sep 21.


MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.

Tang L, Li J, Li ZY, Li XT, Gong JF, Ji JF, Sun YS, Shen L.

BMC Cancer. 2018 Aug 13;18(1):811. doi: 10.1186/s12885-018-4606-0.


Translational insights into gastrointestinal stromal tumor and current clinical advances.

Hemming ML, Heinrich MC, Bauer S, George S.

Ann Oncol. 2018 Oct 1;29(10):2037-2045. doi: 10.1093/annonc/mdy309.


Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

Mei L, Du W, Idowu M, von Mehren M, Boikos SA.

Front Oncol. 2018 May 7;8:135. doi: 10.3389/fonc.2018.00135. eCollection 2018. Review.


Metastatic Cutaneous Duodenal Gastrointestinal Stromal Tumor: A Possible Clue to Multiple Metastases.

Kim YJ, Lee WJ, Won CH, Choi JH, Lee MW.

Ann Dermatol. 2018 Jun;30(3):345-347. doi: 10.5021/ad.2018.30.3.345. Epub 2018 Apr 23.


Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.

Abrams T, Connor A, Fanton C, Cohen SB, Huber T, Miller K, Hong EE, Niu X, Kline J, Ison-Dugenny M, Harris S, Walker D, Krauser K, Galimi F, Wang Z, Ghoddusi M, Mansfield K, Lee-Hoeflich ST, Holash J, Pryer N, Kluwe W, Ettenberg SA, Sellers WR, Lees E, Kwon P, Abraham JA, Schleyer SC.

Clin Cancer Res. 2018 Sep 1;24(17):4297-4308. doi: 10.1158/1078-0432.CCR-17-3795. Epub 2018 May 15.


Supplemental Content

Loading ...
Support Center